Kornimate/medical-research-clean huggingface dataset:
inhalation of kelea excellerated water in covid-19 infected individuals

Conditions: Covid19

Summary: preliminary reports have been received from several sources that the periodic inhaling of the nebulized mist from water that has a heightened level of kinetic activity has quickly (less than 2 days) lessened the severity of symptoms in covid-19 infected patients. on at least several occasions, a repeat pcr test performed several after inhaling a particular water-based product was negative. there are no perceived adverse effects from inhaling the water mist by using a nebulizer or humidifier. it is important, however, to validate these preliminary findings and to include the inhaling of the mist from water, which does not have an elevated level of kinetic activity. this will be by performed in a patient-blinded manner by sequentially inhaling the two types of water over consecutive 2-day periods with covid-19 testing at the end of each of the two day periods. participants will be randomized as to whether they are to inhale the mist from the test or the control water.

several producers of activated water have been in frequent communication with the principal investigator (pi) over the last decade or longer. they have regularly supplied their water products to the pi for laboratory testing, including measuring an activity attributed to the absorption of an environmental force, referred to by the pi as kelea, an abbreviation for kinetic energy limiting electrostatic attraction. kelea is regarded as the source of cellular energy for the body's alternative cellular energy (ace) pathway. this pathway can provide a non-immunological defense mechanism against infections, presumably including coronaviruses. the proposed study is to test water products from several suppliers, as well as a naturally available source of kelea activated water in symptomatic individuals who have tested positive by either pcr or antigen testing for covid-19. the mode of administration will be by inhalation using a nebulizer or diffuser. several deep inhalations will be taken on 5 occasions daily. prior to the first inhalation and at the end of the second day of inhalation, swabs will be taken for covid-19 pcr and/or antigen testing. randomly allocated participants will either blindly first test the kelea excellerated water for two days, followed by using water without an elevated level of kelea and vice versa. the severity of symptoms will also be monitored at the end of each of the two-days periods of inhalation.

Eligibility criteria:
inclusion criteria: individuals entering into quarantine because of a positive covid-19 test using either pcr or an authorized antigen assay. it is not necessary, but preferable, for the participant to be symptomatic for covid-19 - exclusion criteria: unwilling to do repeat pcr and/or antigen testing or to provide the results of the repeat testing or the requested clinical data -

Keywords: energy medicine kelea inhalation
the role of mucosal microbiome in the development, clearance and recurrence of clostridioides difficile infection

Conditions: Clostridioides Difficile Infection

Summary: the study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been diagnosed with c. difficile infection to determine if there are features associated with development, clearance, and recurrence of disease.

patients who were recently diagnosed with c. difficile infection will undergo assessment of both before treatment and after completing treatment to study the presence of c. difficile in the colonic mucosa pre as well as assessment for microbiome and patient/clinical factors that may contribute to disease recurrence. assessment will include sigmoid colon biopsies, blood draw, stool samples and surveys.

Eligibility criteria:
inclusion criteria: * adults aged 18 and over * confirmed c. difficile infection based on positive c. difficile toxin pcr testing and clinical evidence of diarrhea exclusion criteria: * known active pregnancy * prior diagnosis of c. difficile infection within 2 months of this diagnosis * other known active gastrointestinal infectious process * vulnerable adults * any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes
effectiveness of precision spinal cord stimulation with artisan paddle electrode

Conditions: Back Pain; Chronic Pain; Pain in Leg, Unspecified

Summary: the primary objective of this study is to evaluate the acute and chronic efficacy of spinal cord stimulation using the precision implantable neurostimulation device with the artisan paddle electrode in patients with failed back surgery syndrome (fbss) and associated primary or secondary back or lower extremity pain. there are significant numbers of patients with fbss who have moderate to severe drug refractory pain. an optimal outcome will demonstrate that the precision scs device has significant effectiveness in reducing this pain resulting in improved quality of life and functional capacity.

the conventional implantation of the spinal cord stimulator calls for dual percutaneous leads placed in parallel at t8-t9 vertebral levels. a common problem after surgery is the migration of leads from the initial implanted site, the consequence of which is inadequate pain relief. anecdotal reports suggest that the paddle electrode can eliminate some of the problems associated with lead migration by providing a constant distance between the parallel electrodes. furthermore, it has been reported to provide superior pain relief and paresthesia coverage. this study aims to evaluate pain and paresthesia coverage by placing a paddle lead. patients invited to participate in this study will be eligible for scs therapy and will have already selected therapy with the advanced bionics precision system, independent of possible inclusion in this study.

Eligibility criteria:
inclusion criteria: * have fbss with moderate to severe back or lower extremity pain of at least 3 months duration, be an appropriate candidate for scs, and have independently elected scs therapy with the precision system as next line therapy; * be 18 years of age or older; * be willing and able to comply with all study related procedures and visits; * be capable of reading and understanding patient information materials and giving written informed consent. exclusion criteria: * have low back pain as the primary complaint; * have any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints; * have participated in any investigational drug or device trial in the last 4 weeks or plan to participate in any other study during the year.

Keywords: pain neurostimulation leg pain back pain
prevention-achd risk score

Conditions: Death, Sudden, Cardiac; Ventricular Fibrillation; Ventricular Tachycardia; Congenital Heart Disease

Summary: sudden cardiac death (scd) is one of the major causes of mortality in adults with congenital heart disease (achd). risk stratification for sudden cardiac death in this patient group is challenging and at the current moment there are no clear guidelines on implantable cardioverter-defibrillator (icd) implantation for primary prevention of scd in this young patient population. the reason for this is the fact that this is a heterogenous group of patients and scd is a relatively rare event. because of this there have been no prospective studies on scd in achd. however, multiple retrospective studies on icd implantation in achd have shown that this treatment does appear to be effective. researchers from the academic medical center have identified several risk factors for sudden cardiac death. a risk score was created using this data, which has been validated in an internal and external cohort in a retrospective setting. the design of this study, including the conception of the risk score, its calculation method and validation will be published in an international scientific peer-reviewed journal. the hypothesis of this study is that the risk score accurately predicts the risk of sudden cardiac death.


Eligibility criteria:
inclusion criteria: * adult (≥18 years old) patient with a diagnosis of a congenital heart defect. exclusion criteria: * patients of whom follow up is not possible, e.g. no permanent home address, living outside of or expecting to move out of the area wherein travelling to the investigating hospital outpatient clinic is possible. * patients with documented sustained ventricular tachycardia or ventricular fibrillation. * patients for whom the risk is not calculable because of a congenital heart disease diagnose not represented in the risk score. * patients for whom the risk score is not calculable because of missing data * patients with recent (\<3 months ago) myocardial infarction. * patients in whom the high scd-risk status depends on an impaired ejection fraction that is expected to improve, e.g. due to tachycardiomyopathy. * patients with a guideline defined contraindication for icd implantation.

Keywords: risk score risk prediction prevention
audiological disturbances in vitiligo

Conditions: Vitiligo; Hearing Loss

Summary: the purpose of this study is to determine wether vitiligo patients have more audiological abmnormalities, than the healthy population.


Eligibility criteria:
inclusion criteria: * vitligo patients under 50. healthy patients under 50 for control group exclusion criteria: * above age 50. systemic disease. exposure to loud noise in past. familial history of deafness use of autotoxuc drugs or steroids. autoimmune/metabolic/neurologic/vascular disease
a study to investigate the analgesic efficacy of azd2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia..

Conditions: Nerve Pain

Summary: a study to investigate the analgesic efficacy of azd2423 compared with placebo after 28 days treatment in patients with posttraumatic neuralgia.


Eligibility criteria:
inclusion criteria: * provision of signed informed consent form * males and female patients aged 18 to 80 years * patients with neuropathic pain due to peripheral nerve injury caused by trauma or surgery exclusion criteria: * other paint that may confound assessment of neuropathic pain * history of treatment failure with more than three adequate trials of treatment for neuropathic pain * central neuropathic pain conditions (caused by central nervous system injury/disease, eg. stroke)

Keywords: analgesic effect
evaluation of a covid-19 pneumonia cxr ai detection algorithm

Conditions: Covid19

Summary: this study investigates the diagnostic performance of an ai algorithm in the detection of covid-19 pneumonia on chest radiographs.

this is an international multi-center study. chest radiographs (cxr) from different participating centers will be collected to develop an ai algorithm to detect covid-19 pneumonia. this will be tested on external hold out datasets from different centers using sars-cov-2 by real-time reverse transcriptase-polymerase chain reaction (rt-pcr) assay as ground truth.

Eligibility criteria:
inclusion criteria: * all adult patients \>18 years of age * attended any of the participating institutes between february 1, 2020 until september, 2020 * underwent both rt-pcr testing and frontal cxr (within 48 hours of pcr testing) for covid-19 infection * frontal cxr of patients pre-covid pandemic exclusion criteria: * unavailability of patient demographics and clinical data * inconclusive rt-pcr results * cxr considered to be of non-diagnostic quality by the clinical radiology research team at each site * cxr not in a retrievable or processable format for ai inference
chest pain observation unit risk reduction trial

Conditions: Chest Pain

Summary: the purpose of this study is to determine whether a brief counseling intervention initiated in the chest pain observation unit has a significant impact upon the health attitudes (readiness to change) and cardiovascular risk-related behaviors (diet, exercise, and smoking) of emergency department patients.

increasingly, emergency department patients for whom a non-ischemic etiology of acute coronary syndrome (acs) symptoms cannot be identified undergo further evaluation to rule out myocardial ischemia and appraisal of cardiovascular risk factors (crfs) in chest pain observation units (cpous). cpou admission may represent a "teachable moment," but there has been little research on the effectiveness of brief, practical interventions for cardiovascular risk reduction in this population, despite the fact that the vast majority of these patients have at least one modifiable crf and many do not receive regular primary care follow-up. the purpose of this study is to determine whether a brief counseling intervention initiated in the cpou has a significant impact upon health attitudes (readiness to change) and cardiovascular risk-related behaviors (diet, exercise, and smoking). based on the health belief model (hbm), the intervention is designed to provide patients with tailored information on their cardiovascular risk, to negotiate goals for change, and to build problem-solving skills. all participants who are admitted to the cpou for evaluation of acs symptoms will be randomized to brief intervention (face-to-face counseling in the cpou, coupled with telephone counseling at 4 weeks) or to minimal intervention (booklet with general information on crfs) after a negative initial troponin measurement. we will conduct a baseline survey and follow-up telephone interviews at 2- and 6-month to assess stage of change and crf-related behaviors. linear mixed models and logistic regression (with generalized estimating equations) will be used to compare continuous and dichotomous behavioral outcomes across treatment arms, respectively. the proposed trial will evaluate the feasibility and effectiveness of delivering brief interventions for cardiovascular risk reduction in the cpou setting, will provide insight into mechanisms of behavior change in these patients, and will guide the development of future case management interventions.

Eligibility criteria:
inclusion criteria: * at least one modifiable cardiovascular risk factor (smoking, hyperlipidemia, hypertension, diabetes mellitus, obesity) exclusion criteria: * patients who "rule-in" for myocardial ischemia at initial testing * terminally ill (expected to survive less than 3 months) * unavailable for 6-month follow-up * cannot be contacted by telephone * institutionalized persons (prisoners, nursing home residents) * unable to provide informed consent (impaired mental status, unable to speak english)

Keywords: health promotion emergency medical services randomized controlled trial chest pain observation unit cardiovascular risk factors
support program for adoption of cancer screening interventions at a rural community-based organization

Conditions: Breast Carcinoma; Cervical Carcinoma; Colorectal Carcinoma; Malignant Solid Neoplasm

Summary: this pilot trial study uses a structural support program for adoption of cancer screening interventions at a rural community-based organization. rural communities face unique barriers in implementation of evidence-based interventions due to a lack of infrastructure, community capacity, and expertise as academic and research centers are often clustered in urban areas. the support program may help a rural community-based organization select, adapt, and implement cancer prevention and control evidence-based interventions.

outline: community-based organizations participate in the support program, consisting of 2 half-day training workshops over 2 weeks, and 30-minute bi-weekly consultations in order to adapt and implement the cancer screening intervention for community members. after completion of study, participants are followed up at 3 months.

Eligibility criteria:
inclusion criteria: * objective ii community-based organization: located in the yakima valley of washington state * objective ii community-based organization: serve community members who are 18 and older * objective ii community-based organization: willing to commit to the 6-month program * objective ii participants: receiving services from the recruited community-based organization * objective iii participants: not up-to-date for breast, cervical, and colorectal cancer screening according to current u.s. preventive services tasks force (uspstf) guidelines. the current uspstf recommendations for breast, cervical, and colorectal cancer are: * breast cancer screening: women ages 50-74 should be screened for breast cancer with mammography every 2 years. * cervical cancer screening: women ages 21-29 should be screened for cervical cancer every 3 years with cervical cancer cytology alone. for women ages 30-65, the uspstf recommends screening every 3 years with cervical cytology alone, every 5 years or every 5 years with high risk human papillomavirus (hrhpv) testing in combination of cytology. * colorectal cancer screening: individuals ages 50-75 should be screened for colorectal cancer with guaiac-based fecal occult blood tests (gfobt) or fecal immunochemical test (fit) once a year, or colonoscopy every 10 years (uspstf approves additional screening tests, but these are the most commonly used). * objective iii participants: if the community-based organization selects breast cancer screening, we will recruit women ages 50-74. * objective iii participants: if the community-based organization selects cervical cancer screening, we will recruit women ages 21-65. * objective iii participants: if the community-based organization selects colorectal cancer screening, we will recruit women and men ages 50-75. * objective iii participants: average risk for breast, cervical, or colorectal cancer
assessing the efficacy of virtual reality analgesia (vra) in pediatric patients for pain control

Conditions: Pain

Summary: to evaluate the efficacy of virtual reality analgesia (vra) for pediatric patients undergoing botulinum toxin injections (bti) for spasticity management. patients will be assigned to one of three groups; one group of subjects will randomly be assigned to vra intervention using google cardboard virtual reality head- mounted display powered by a ipod touch, a second group of subjects will receive vra with oculus rift, and a third group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group.

group 1: oculus rift this group will receive bti's per conventional protocols. they will wear the oculus rift vrhmd (figure 1) powered by the laptop pc (figure 2) during the procedure viewing a vr 360 degree video of their choice. measurements in pain and anxiety will be taken per the outcome measures listed above. group 2: google cardboard vrhmd this group will receive bti's per conventional protocols. they will wear the google cardboard vrhmd (figure 3) powered by ipod touch/smartphone (figure 4) during the procedure viewing a vr 360 degree video of their choice. measurements in pain and anxiety will be taken per the outcome measures listed above. group 3. control this group will receive bti's per conventional protocols without vra intervention.

Eligibility criteria:
inclusion criteria: * children with spasticity requiring bti * children ages 5 - 18 * children who have contraindications for sedation for bti * children with intact vision who can attend vr intervention exclusion criteria: * children who have uncontrolled seizures \> than 4 per year * children who are not attentive to vr secondary to poor concentration, poor cognition to external stimuli * children on different treatments for spasticity such as baclofen pump, phenol block. for patients who receive phenol block, phenol block will be held during the visits with vr intervention to avoid confounding results * children with poor bleeding control * children who request general anesthesia/iv sedation.
a study to compare the pharmacokinetics of lafutidine and irsogladine maleate tablet

Conditions: Gastric Ulcer

Summary: an open-label, randomized, single-dose, 2x2 crossover study to compare the pharmacokinetics of bri-1501 tablet and coadministration of lafutidine and irsogladine maleate as individual tablets in healthy adult volunteers


Eligibility criteria:
inclusion criteria: * healthy subject, aged 19- 50 years exclusion criteria: * history of clinically significant and active disease * history of gastrointestinal disease * history of clinically significant hypersensitivity to study drug, any other drug * laboratory test serum ast or alt \> 1.25 times of upper normal range serum total bilirubin \> 1.5 times of upper normal range egfr \< 60 ml/min/1.73m² serological test(hbsag, hcv ab, hiv ag/ab, syphilis reagin) positive * hypotension or hypertension * pregnant or nursing women * participation in any other study within 90 days
clinical association between celiac disease and intussusception in children

Conditions: Celiac Disease in Children; Intussusception

Summary: clinical association between celiac disease and intussusception in children


Eligibility criteria:
inclusion criteria: children aged 6 months to 18 years diagnosed with celiac disease based on serology and biopsy diagnosed with intussusception confirmed by imaging parent or legal guardian provides informed consent exclusion criteria: children with known gastrointestinal abnormalities other than celiac disease history of abdominal surgery incomplete or unavailable medical records patients on immunosuppressive therapy

Keywords: pediatric gastrointestinal disease
ring-type pulse oximeter for evaluation for sleep assessment study

Conditions: Sleep-Disordered Breathing; Sleep Architecture

Summary: recently, various electronic lifestyle activity monitoring devices (elam) are increasingly commercially available. however, the quality and reliability of the data from elam are unclear, compared with polysomnography (psg), which is the gold-standard sleep assessment method. thus, combining elam with psg will validate elam and improve its clinical and research utilization. the investigators propose to conduct this study to validate elam device for sleep assessment. the investigators will compare belun ring data collection and overnight in-lab psg measures of sleep-disordered breathing (sdb) and sleep architecture in adults with obstructive sleep apnea (osa) symptoms. the investigators propose to recruit a total of 40 participants with symptoms of osa. the overall accuracy, sensitivity and specificity of belun ring to assess sdb and sleep architecture will be validated by using psg analysis as a gold standard.


Eligibility criteria:
inclusion criteria: * age between 18 to 80 years old. ideally balanced for sex and age (18 to 80 years old) * no more than 75% of subjects in one bin of: (male, female) * no more than 50% of subjects in one age-group (18-29, 30-39, 40-49, 50-59, 60-80) * patients with osa symptoms (snoring, excessive daytime sleepiness or witnessed apnea, etc.) * without any unstable medical or psychiatric co-morbidities that would be expected to interfere with the study. * if taking any medication, must be on a stable dose of medication for a month * able to read and understand english exclusion criteria: * presence of any significant systemic or unstable medical condition which could lead to difficulty complying with the protocol, suicidality, current regular use of psychiatric medications, opiates, or thyroid medications, dementia, current substance abuse, post-traumatic or psychotic disorders, bipolar disorder; any significant neurologic disease, including possible and probable dementia, parkinson's or huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, history of significant head trauma, history of alcohol or substance use disorder within the past 2 years (dsm v criteria); * if positive airway pressure (pap) titration study or split night study (diagnostic and pap titration study combined)